Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Beijing Biostar Pharmaceuticals Co., Ltd. Class H ( (HK:2563) ) has shared an announcement.
Beijing Biostar Pharmaceuticals has warned that its auditors may issue a qualified opinion on its upcoming annual results, linked specifically to concerns over the recoverability of an investment fund on the company’s books. The board is in active discussions with the auditors to address these issues and plans to provide fuller details in its annual results announcement, while cautioning shareholders and potential investors to act carefully in trading the company’s shares pending further disclosure.
More about Beijing Biostar Pharmaceuticals Co., Ltd. Class H
Beijing Biostar Pharmaceuticals Co., Ltd. is a pharmaceutical company based in the People’s Republic of China and listed in Hong Kong under stock code 2563. It focuses on the development and commercialization of biopharmaceutical and medical products, serving healthcare markets in China and potentially broader regional markets.
Average Trading Volume: 52,996
Technical Sentiment Signal: Sell
Current Market Cap: HK$823.5M
For an in-depth examination of 2563 stock, go to TipRanks’ Overview page.